Business Wire5d
Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
Yahoo Finance3d
Scholar Rock Holding Corporation (SRRK)
CAMBRIDGE, Mass., February 10, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...
Business Wire17d
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
ETF Daily News25d
Scholar Rock Holding Co. (NASDAQ:SRRK) Receives Consensus Rating of “Buy” from Analysts
Hamilton Lane Advisors LLC bought a new position in shares of Scholar Rock during the 4th quarter valued at approximately $1,274,000. GAMMA Investing LLC grew its position in Scholar Rock by 51.8% ...
Morningstar12d
Scholar Rock Holding Corp
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Investing17d
Scholar Rock submits FDA application for SMA treatment
CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months ...
Seeking Alpha16d
Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
The last time I wrote about Scholar Rock (NASDAQ:SRRK) it was with respect to a Seeking Alpha article entitled as "Scholar Rock: SMA Program Strides Forward With Positive Clinical Data".
Investing17d
Scholar Rock submits FDA application for SMA treatment
CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months, ...
ETF Daily News17d
Exchange Traded Concepts LLC Sells 82,792 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)
Scholar Rock Trading Up 0.5 % SRRK stock opened at $42.56 on Thursday. The firm has a fifty day moving average price of $41.94 and a 200 day moving average price of $24.97. Scholar Rock Holding Co ...
pharmaphorum3d
Scholar Rock preps filings after SMA antibody clears trial
Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings ...
Investing24d
Scholar Rock Holding Corp (SRRK)
Monday, Truist Securities adjusted its outlook on Scholar Rock (NASDAQ:SRRK) shares, raising the biotechnology company's price target from $36.00 to $45.00 while maintaining a Buy... ByInvesting ...